

SPECIAL FEATURES

Highlights of This Issue 451

CCR Translations

453 Is GPNMB the Achilles' Heel of Mo-MDSC While Marking Their Suppressive Activity?

Mario P. Colombo

See related article, p. 828

455 No Sugar Added: A New Strategy to Inhibit Glioblastoma Receptor Tyrosine Kinases

Daniel R. Wahl and Theodore S. Lawrence

See related article, p. 784

457 Thyroid Nodule DNA Methylation Signatures: An Important Diagnostic Annotation

Elliot J. Mitmaker, Roger Tabah, and Jacques How

*See related article, p. 544*460 Prognostic Models Turn the Heat(IT)up on FLT3^{ITD}-Mutated AML

Paolo Gallipoli and Brian J.P. Huntly

See related article, p. 573

Statistics in CCR

463 Multimodal Meta-Analysis of 1,494 Hepatocellular Carcinoma Samples Reveals Significant Impact of Consensus Driver Genes on Phenotypes



Kumardeep Chaudhary, Olivier B. Poirion, Liangqun Lu, Sijia Huang, Travers Ching, and Lana X. Garmire

CCR Drug Updates

473 FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease

Emily Y. Jen, Qing Xu, Aaron Schetter, Donna Przepiorka, Yuan Li Shen, Donna Roscoe, Rajeshwari Sridhara, Albert Deisseroth, Reena Philip, Ann T. Farrell, and Richard Pazdur

CLINICAL TRIALS: TARGETED THERAPY

478 A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma

Jacob P. Laubach, Chia-Jen Liu, Noopur S. Raje, Andrew J. Yee, Philippe Armand, Robert L. Schlossman, Jacalyn Rosenblatt, Jacquelyn Hedlund, Michael Martin, Craig Reynolds, Kenneth H. Shain, Ira Zackon, Laura Stampleman, Patrick Henrick, Bradley Rivotto, Kalvis T.V. Hornburg, Henry J. Dumke, Stacey Chuma, Alexandra Savell, Damian R. Handisides, Stew Kroll, Kenneth C. Anderson, Paul G. Richardson, and Irene M. Ghobrial

487 Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study



Magnus T. Dillon, Lorna Grove, Kate L. Newbold, Heather Shaw, Nicholas F. Brown, Jeanne Mendell, Shuquan Chen, Robert A. Beckman, Anne Jennings, Marivic Ricamara, Jonathan Greenberg, Martin Forster, and Kevin J. Harrington

496 A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors



Florence Atrafi, Harry J.M. Groen, Lauren A. Byers, Elena Garralda, Martijn P. Lolkema, Randeep S. Sangha, Santiago Viteri, Young Kwang Chae, D. Ross Camidge, Nashat Y. Gabrail, Beibei Hu, Tian Tian, Silpa Nuthalapati, Elizabeth Hoening, Lei He, Philip Komarnitsky, and Antonio Calles

506 PTEN Expression, Not Mutation Status in TSC1, TSC2, or mTOR, Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial



Martin H. Voss, David Chen, Albert Reising, Mahtab Marker, Jiayuan Shi, Jianning Xu, Irina Ostrovnya, Venkatraman E. Seshan, Almedina Redzematovic, Ying-Bei Chen, Parul Patel, Xia Han, James J. Hsieh, A. Ari Hakimi, and Robert J. Motzer



Table of Contents

CLINICAL TRIALS: IMMUNOTHERAPY

- 515** Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study
Jianming Xu, Yun Zhang, Ru Jia, Chunyan Yue, Lianpeng Chang, Rongrui Liu, Gairong Zhang, Chuanhua Zhao, Yaoyue Zhang, Chunxia Chen, Yan Wang, Xin Yi, Zhiyuan Hu, Jianjun Zou, and Quanren Wang
- 524** E3611—A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon- α 2b in Advanced Melanoma
Ahmad A. Tarhini, Sandra J. Lee, Xiaoxue Li, Uma N.M. Rao, Arun Nagarajan, Mark R. Albertini, Jerry W. Mitchell Jr, Stuart J. Wong, Mark A. Taylor, Noel Audi, Phu V. Truong, Robert M. Conry, and John M. Kirkwood

PRECISION MEDICINE AND IMAGING

- 533** VCAM-1–targeted MRI Enables Detection of Brain Micrometastases from Different Primary Tumors
Vinton W.T. Cheng, Manuel Sarmiento Soto, Alexandre A. Khrapitchev, Francisco Perez-Balderas, Rasheed Zakaria, Michael D. Jenkinson, Mark R. Middleton, and Nicola R. Sibson
- 544** Identification of Tissue-Specific DNA Methylation Signatures for Thyroid Nodule Diagnostics
John H. Yim, Audrey H. Choi, Arthur X. Li, Hanjun Qin, Sue Chang, Sun-Wing T. Tong, Peiguo Chu, Byung-Wook Kim, Daniel Schmolze, Ryan Lew, Yasmine Ibrahim, Valeriy A. Poroyko, Sylvana Salvatierra, Alysha Baker, Jinhui Wang, Xiwei Wu, Gerd P. Pfeifer, Yuman Fong, and Maria A. Hahn
See related commentary, p. 457
- 552** Identifying Recurrent Malignant Glioma after Treatment Using Amide Proton Transfer-Weighted MR Imaging: A Validation Study with Image-Guided Stereotactic Biopsy
Shanshan Jiang, Charles G. Eberhart, Michael Lim, Hye-Young Heo, Yi Zhang, Lindsay Blair, Zhibo Wen, Matthias Holdhoff, Doris Lin, Peng Huang, Huamin Qin, Alfredo Quinones-Hinojosa, Jon D. Weingart, Peter B. Barker, Martin G. Pomper, John Laterra, Peter C.M. van Zijl, Jaishri O. Blakeley, and Jinyuan Zhou

- 562** Association of CD4⁺ Radiation-Induced Lymphocyte Apoptosis with Fibrosis and Telangiectasia after Radiotherapy in 272 Breast Cancer Patients with >10-Year Follow-up
Marlon R. Veldwijk, Petra Seibold, Akke Botma, Irmgard Helmbold, Elena Sperk, Frank A. Giordano, Nicole Gürth, Anne Kirchner, Sabine Behrens, Frederik Wenz, Jenny Chang-Claude, and Carsten Herskind
- 573** Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 Inhibitors
Gregory W. Schwartz, Bryan Manning, Yeqiao Zhou, Priya Velu, Ashkan Bigdeli, Rachel Astles, Anne W. Lehman, Jennifer J.D. Morrissette, Alexander E. Perl, Mingyao Li, Martin Carroll, and Robert B. Fayyabi
See related commentary, p. 460
- 584** A Combined Nomogram Model to Preoperatively Predict Histologic Grade in Pancreatic Neuroendocrine Tumors
Wenjie Liang, Pengfei Yang, Rui Huang, Lei Xu, Jiawei Wang, Weihai Liu, Lele Zhang, Dalong Wan, Qiang Huang, Yao Lu, Yu Kuang, and Tianye Niu
- 595** Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer
Amilcar Flores-Morales, Tobias B. Bergmann, Charlotte Lavalley, Tanveer S. Batth, Dong Lin, Mads Lerdrup, Stine Friis, Anette Bartels, Gitte Kristensen, Agnieszka Krzyzanowska, Hui Xue, Ladan Fazli, Klaus H. Hansen, Martin A. Røder, Klaus Brasso, José M. Moreira, Anders Bjartell, Yuzhuo Wang, Jesper V. Olsen, Colin C. Collins, and Diego Iglesias-Gato
- 609** Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors
Yemarshet K. Gebreyohannes, Agnieszka Wozniak, Madalina-Elena Zhai, Jasmien Wellens, Jasmien Cornillie, Ulla Vanleeuw, Erica Evans, Alexandra K. Gardino, Christoph Lengauer, Maria Debiec-Rychter, Raf Sciot, and Patrick Schöffski

TRANSLATIONAL CANCER MECHANISMS AND THERAPY

- 619** Serum Nardilysin, a Surrogate Marker for Epithelial–Mesenchymal Transition, Predicts Prognosis of Intrahepatic Cholangiocarcinoma after Surgical Resection
Tomoaki Yoh, Etsuro Hatano, Yosuke Kasai, Hiroaki Fuji, Kiyoto Nishi, Kan Toriguchi, Hideaki Sueoka, Mikiko Ohno, Satoru Seo, Keiko Iwaisako, Kojiro Taura, Rina Yamaguchi, Masato Kurokawa, Jiro Fujimoto, Takeshi Kimura, Shinji Uemoto, and Eiichiro Nishi

Table of Contents


- 629** Serum- and Glucocorticoid-induced Kinase Sgk1 Directly Promotes the Differentiation of Colorectal Cancer Cells and Restrains Metastasis
Lennard Y.W. Lee, Connor Woolley, Thomas Starkey, Sujata Biswas, Tia Mirshahi, Chiara Bardella, Stefania Segditsas, Shazia Irshad, and Ian Tomlinson
- 641** DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway
Liana Adam, F. Anthony San Lucas, Richard Fowler, Yao Yu, Wenhui Wu, Yulun Liu, Huamin Wang, David Menter, Michael T. Tetzlaff, Joe Ensor Jr, Ganiraju Manyam, Stefan T. Arold, Chad Huff, Scott Kopetz, Paul Scheet, and Michael J. Overman
- 652** Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer
Ulka N. Vaishampayan, Izabela Podgorski, Lance K. Heilbrun, Jawana M. Lawhorn-Crews, Kimberlee C. Dobson, Julie Boerner, Karri Stark, Daryn W. Smith, Elisabeth I. Heath, Joseph A. Fontana, and Anthony F. Shields
- 663** Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma
Nichola Cruickshanks, Ying Zhang, Sarah Hine, Myron Gibert, Fang Yuan, Madison Oxford, Cassandra Grello, Mary Pahuski, Collin Dube, Fadila Guessous, Baomin Wang, Ciana Deveau, Karim Saoud, Isela Gallagher, Julia Wulfkuhle, David Schiff, See Phan, Emanuel Petricoin, and Roger Abounader
- 674** Lobular Carcinomas *In Situ* Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma
Ju Youn Lee, Michail Schizas, Felipe C. Geyer, Pier Selenica, Salvatore Piscuoglio, Rita A. Sakr, Charlotte K.Y. Ng, Jose V. Scarpa Carniello, Russell Towers, Dilip D. Giri, Victor P. de Andrade, Anastasios D. Papanastasiou, Agnes Viale, Reuben S. Harris, David B. Solit, Britta Weigelt, Jorge S. Reis-Filho, and Tari A. King
- 687**  RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer
Daniel Nava Rodrigues, Nicola Casiraghi, Alessandro Romanel, Mateus Crespo, Susana Miranda, Pasquale Rescigno, Ines Figueiredo, Ruth Riisnaes, Suzanne Carreira, Semini Sumanasuriya, Paola Gasperini, Adam Sharp, Joaquin Mateo, Alan Makay, Christopher McNair, Matthew Schiewer, Karen Knudsen, Gunther Boysen, Francesca Demichelis, and Johann S. de Bono
- 698** Antibody-based Delivery of TNF to the Tumor Neovasculature Potentiates the Therapeutic Activity of a Peptide Anticancer Vaccine
Philipp Probst, Marco Stringhini, Danilo Ritz, Tim Fugmann, and Dario Neri
- 710** Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer
Marine F. Garrido, Nicolas J.-P. Martin, Matthieu Bertrand, Catherine Gaudin, Frédéric Commo, Nassif El Kalaany, Nader Al Nakouzi, Ladan Fazli, Elaine Del Nery, Jacques Camonis, Franck Perez, Stéphanie Lerondel, Alain Le Pape, Daniel Compagno, Martin Gleave, Yohann Lorient, Laurent Désaubry, Stéphan Vagner, Karim Fizazi, and Anne Chauchereau
- 724** Host *IDO2* Gene Status Influences Tumor Progression and Radiotherapy Response in *KRAS*-Driven Sporadic Pancreatic Cancers
Avinoam Nevler, Alexander J. Muller, Erika Sutanto-Ward, James B. DuHadaway, Kei Nagatomo, Eric Londin, Kevin O'Hayer, Joseph A. Cozzitorto, Harish Lavu, Theresa P. Yeo, Mark Curtis, Tatiana Villatoro, Benjamin E. Leiby, Laura Mandik-Nayak, Jordan M. Winter, Charles J. Yeo, George C. Prendergast, and Jonathan R. Brody
- 735** Pan-HDAC Inhibitors Restore PRDM1 Response to IL21 in CREBBP-Mutated Follicular Lymphoma
Fabienne Desmots, Mikaël Roussel, Céline Pangault, Francisco Llamas-Gutierrez, Cédric Pastoret, Eric Guiheneuf, Jérôme Le Priol, Valérie Camara-Clayette, Gersende Caron, Catherine Henry, Marc-Antoine Belaud-Rotureau, Pascal Godmer, Thierry Lamy, Fabrice Jardin, Karin Tarte, Vincent Ribrag, and Thierry Fest
- 747** Methylation-dependent Tissue Factor Suppression Contributes to the Reduced Malignancy of IDH1-mutant Gliomas
Dusten Unruh, Snezana Mirkov, Brian Wray, Michael Drumm, Jonathan Lamano, Yuping D. Li, Qazi F. Haider, Rodrigo Javier, Kathleen McCortney, Amanda Saratsis, Denise M. Scholtens, Jann N. Sarkaria, C. David James, and Craig Horbinski
- 760** Telomerase Activation and ATRX Mutations Are Independent Risk Factors for Metastatic Pheochromocytoma and Paraganglioma
Sylvie Job, Irena Draskovic, Nelly Burnichon, Alexandre Buffet, Jérôme Cros, Charles Lépine, Annabelle Venisse, Estelle Robidel, Virginie Verkarre, Tchao Meatchi, Mathilde Sibony, Laurence Amar, Jérôme Bertherat, Aurélien de Reyniès, Arturo Londoño-Vallejo, Judith Favier, Luis Jaime Castro-Vega, and Anne-Paule Gimenez-Roqueplo

Table of Contents

- 771** Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER⁺/HER2⁺ Breast Cancers: Implications to the ExteNET Trial
Dhivya R. Sudhan, Luis J. Schwarz, Angel Guerrero-Zotano, Luigi Formisano, Mellissa J. Nixon, Sarah Croessmann, Paula I. González Ericsson, Melinda Sanders, Justin M. Balko, Francesca Avogadri-Connors, Richard E. Cutler, Alshad S. Lalani, Richard Bryce, Alan Auerbach, and Carlos L. Arteaga
- 784** Oligosaccharyltransferase Inhibition Reduces Receptor Tyrosine Kinase Activation and Enhances Glioma Radiosensitivity
Marta Baro, Cecilia Lopez Sambrooks, Amanda Quijano, W. Mark Saltzman, and Joseph Contessa
See related commentary, p. 455
- 796** KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
Sandra Misale, Jackson P. Fatherree, Eliane Cortez, Chendi Li, Samantha Bilton, Daria Timonina, David T. Myers, Dana Lee, Maria Gomez-Caraballo, Max Greenberg, Varuna Nangia, Patricia Greninger, Regina K. Egan, Joseph McClanaghan, Giovanna T. Stein, Ellen Murchie, Patrick P. Zarrinkar, Matthew R. Janes, Lian-Sheng Li, Yi Liu, Aaron N. Hata, and Cyril H. Benes
- 808** Smad7 Promotes Healing of Radiotherapy-Induced Oral Mucositis without Compromising Oral Cancer Therapy in a Xenograft Mouse Model
Jingjing Luo, Li Bian, Melanie A. Blevins, Dongyan Wang, Chao Liang, Danfeng Du, Fanglong Wu, Barry Holwerda, Rui Zhao, David Raben, Hongmei Zhou, Christian D. Young, and Xiao-Jing Wang
- 819** The Impact of Early-Phase Trial Design in the Drug Development Process
Mark R. Conaway and Gina R. Petroni
- 828** Blocking Monocytic Myeloid-Derived Suppressor Cell Function via Anti-DC-HIL/ GPNMB Antibody Restores the *In Vitro* Integrity of T Cells from Cancer Patients
Masato Kobayashi, Jin-Sung Chung, Muhammad Beg, Yull Arriaga, Udit Verma, Kevin Courtney, John Mansour, Barbara Haley, Saad Khan, Yutaka Horiuchi, Vijay Ramani, David Harker, Purva Gopal, Farshid Araghizadeh, Ponciano D. Cruz Jr, and Kiyoshi Ariizumi
See related commentary, p. 453
- 839** The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC)
Tomi Pakarainen, Jaakko Nevalainen, Kirsi Talala, Kimmo Taari, Jani Raitanen, Paula Kujala, Ulf-Håkan Stenman, Teuvo L.J. Tammela, and Anssi Auvinen
- 844** Ketoconazole and Posaconazole Selectively Target HK2-expressing Glioblastoma Cells
Sameer Agnihotri, Sheila Mansouri, Kelly Burrell, Mira Li, Yasin Mamatjan, Jeff Liu, Romina Nejad, Sushil Kumar, Shahrzad Jalali, Sanjay K. Singh, Alenoush Vartanian, Eric Xueyu Chen, Shirin Karimi, Olivia Singh, Severa Bunda, Alireza Mansouri, Kenneth D. Aldape, and Gelareh Zadeh
- 856** Enhancing Abiraterone Acetate Efficacy in Androgen Receptor-positive Triple-negative Breast Cancer: Chk1 as a Potential Target
Thomas Grellety, Celine Callens, Elodie Richard, Adrien Briaux, Valérie Vélasco, Marina Pulido, Anthony Gonçalves, Pierre Gestraud, Gaetan MacGrogan, Hervé Bonnefoi, and Bruno Cardinaud
- 868** Leveraging Bioorthogonal Click Chemistry to Improve ²²⁵Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma
Sophie Poty, Lukas M. Carter, Komal Mandleywala, Rosemary Membreno, Dalya Abdel-Atti, Ashwin Ragupathi, Wolfgang W. Scholz, Brian M. Zeglis, and Jason S. Lewis
- 881** Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer
Daniel L.J. Thorek, Anson T. Ku, Nicholas Mitsiades, Darren Veach, Philip A. Watson, Dipti Metha, Sven-Erik Strand, Sai Kiran Sharma, Jason S. Lewis, Diane S. Abou, Hans G. Lilja, Steven M. Larson, Michael R. McDevitt, and David Ulmert

LETTERS TO THE EDITOR


- 892** CAF-Derived IL6 and GM-CSF Cooperate to Induce M2-like TAMs—Letter
Vittoria Iorio, Margot De Marco, Anna Basile, Daniela Eletto, Mario Capunzo, Paolo Remondelli, Gianluca Sala, Liberato Marzullo, Alessandra Rosati, Vincenzo De Laurenzi, and Maria C. Turco
- 894** CAF-Derived IL6 and GM-CSF Cooperate to Induce M2-like TAMs—Response
Haaglim Cho, Jun-Hyeong Kim, Chang-Duk Jun, Da-Woon Jung, and Darren R. Williams

 AC icon indicates AuthorChoice
For more information please visit www.aacrjournals.org

Table of Contents

ABOUT THE COVER

The cover shows a section of a 3-dimensional-reconstructed pseudocrypt derived from a small bowel adenocarcinoma cell line. For details, see the article by Adam and colleagues on page 641 of this issue.



Clinical Cancer Research

25 (2)

Clin Cancer Res 2019;25:451-895.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/25/2>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/25/2>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.